cronos group glp-1 receptor agonists weight management diabetes treatments Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 | Advances in Therapy Ten Top Tips for the

Instead, federal courts created separate multidistrict litigations (MDLs) to coordinate claims involving gastrointestinal injuries and NAION-related vision loss associated with GLP-1 medications

Overgaard RV, Lindberg SO, Thielke D

Murray CD, Martin NM, Patterson M, et al

The Big Trial of a GLP-1 drug (Wegovy) to Reduce Major Cardiovascular Events Presented at the American Heart Association and simultaneously published in NEJM today is the trial of over 17,600 patients who were randomly assigned either the GLP-1 semaglutide (a glucagon-like peptide-1 receptor agonist) or placebo and were followed for well over 3 years

Other health risks include pancreatitis, thyroid cancer, kidney failure, gallbladder disease, changes in vision, hypoglycemia (low blood sugar), and allergic reactions